RESUMO
The authors overviewed 239 febrile neutropenia (FN) episodes in 82 pediatric leukemia cases treated with BFM treatment protocols. FN was observed mostly during consolidation therapy. Mucositis was the most identified focus; gram-negative microorganisms were the most identified pathogens. Five patients developed invasive fungal infections. Fever resolved after mean 5.3 days and mean antibiotic administration time was 12.7 days. Addition of G-CSF to antimicrobial therapy shortened the duration of neutropenia, but it did not affect duration of fever resolution and antibiotic administration. The duration of neutropenia, fever resolution, and antibiotic administration was significantly longer in children with acute myeloid leukemia. The authors conclude that children with acute leukemia have severe prolonged neutropenia and are in high risk. In these patients, prediction of the risk of bacteremia based on clinical and laboratory features is important for immediate empiric broad-spectrum antimicrobial therapy and for higher survival rate.
Assuntos
Antibacterianos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Leucemia Mieloide Aguda/tratamento farmacológico , Neutropenia/tratamento farmacológico , Adolescente , Asparaginase/administração & dosagem , Bacteriemia/tratamento farmacológico , Bacteriemia/etiologia , Criança , Pré-Escolar , Daunorrubicina/administração & dosagem , Feminino , Humanos , Lactente , Recém-Nascido , Leucemia Mieloide Aguda/complicações , Masculino , Mucosite/tratamento farmacológico , Mucosite/etiologia , Neutropenia/etiologia , Prednisona/administração & dosagem , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Vincristina/administração & dosagemAssuntos
Atenção à Saúde/métodos , Indústria Farmacêutica/métodos , Antagonistas do Receptor A1 de Adenosina , Biotecnologia/métodos , Biotecnologia/tendências , Doenças Cardiovasculares/tratamento farmacológico , Atenção à Saúde/tendências , Diuréticos/uso terapêutico , Indústria Farmacêutica/tendências , Humanos , Moduladores de Transporte de Membrana/uso terapêutico , Mucosite/tratamento farmacológico , Tiazepinas/uso terapêutico , Xantinas/uso terapêuticoRESUMO
BACKGROUND: Small intestinal mucositis is a common side-effect following high-dose chemotherapy, causing patients to experience pain and abdominal complications often leading to extended stays in hospital. A biomarker to detect these small intestinal changes does not exist in clinical practice. This study aimed to assess the noninvasive 13C-Sucrose breath test (SBT) to detect small intestinal damage associated with mucositis in pediatric cancer patients having chemotherapy. PATIENTS AND METHODS: Small intestinal function was assessed in 15 pediatric cancer patients and 26 healthy children. Subjects were studied for small intestinal permeability (SIP; lactulose/rhamnose), digestive and absorptive capacity (SBT; sucrose), and oro-cecal transit time (OCTT; lactulose), by ingesting two sugar drinks containing the respective sugars. Combined tests were carried out at baseline, day 1, day 3-5 and day 6-9, and in healthy individuals on two separate occasions. A total of 25 cycles of chemotherapy were assessed. Breath samples for the SBT were collected every 15 min for 3 h (expressed as % cumulative dose at 90 min (CD)), a 5 h urine collection for SIP and breath hydrogen determined every 30 min for three hours for OCTT. RESULTS: Clinical mucositis occurred in seven of the 25 cycles of chemotherapy (28%). No significant difference was observed for SIP and OCTT. The SBT %CD at 90 min was significantly lower in the mucositis group compared to the unaffected group and controls at baseline (p<0.05). Patients who developed mucositis maintained a significantly lower %CD, for all test points (p<0.05) compared to the unaffected patients. In patients who developed mucositis the SBT was below the reference range of the controls at all time points. CONCLUSION: The findings show for the first time that it is possible to noninvasively detect and monitor gut damage associated with chemotherapy-induced mucositis in pediatric cancer patients.
Assuntos
Antineoplásicos/uso terapêutico , Biomarcadores/análise , Mucosa Intestinal/patologia , Intestino Delgado/patologia , Mucosite/induzido quimicamente , Adolescente , Antineoplásicos/efeitos adversos , Testes Respiratórios , Criança , Pré-Escolar , Feminino , Humanos , Mucosa Intestinal/efeitos dos fármacos , Masculino , Mucosite/tratamento farmacológico , Seleção de Pacientes , Valores de Referência , Sacarose/análiseRESUMO
BACKGROUND: Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications. MATERIALS AND METHODS: In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis. RESULTS: This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention. CONCLUSION: Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.